BIOHAVEN LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.32 USD | +5.22% |
|
+5.59% | -8.13% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 946.1 | 3,434 | 3,354 | - | - |
| Enterprise Value (EV) 1 | 480.7 | 3,052 | 2,855 | 2,961 | 2,919 |
| P/E ratio | -1.09 x | -7.47 x | -5.27 x | -6.11 x | -7.62 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | 335 x | 233 x | 27.8 x |
| EV / Revenue | - | - | 285 x | 206 x | 24.2 x |
| EV / EBITDA | -0.85 x | -7.11 x | -6.38 x | -5.62 x | -7.46 x |
| EV / FCF | -1.58 x | -9.12 x | -8.57 x | -4.73 x | -11.3 x |
| FCF Yield | -63.2% | -11% | -11.7% | -21.1% | -8.88% |
| Price to Book | 1.15 x | 8.11 x | 6 x | 10.5 x | 10.2 x |
| Nbr of stocks (in thousands) | 68,161 | 80,234 | 88,292 | - | - |
| Reference price 2 | 13.88 | 42.80 | 37.99 | 37.99 | 37.99 |
| Announcement Date | 3/23/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 10.01 | 14.39 | 120.8 |
| EBITDA 1 | - | -566.5 | -429.1 | -447.2 | -526.8 | -391.2 |
| EBIT 1 | - | -567.9 | -436.1 | -651.2 | -620 | -543.6 |
| Operating Margin | - | - | - | -6,506.47% | -4,309.39% | -449.98% |
| Earnings before Tax (EBT) 1 | - | -569.8 | -409.6 | -637 | -619.9 | -550 |
| Net income 1 | -236.4 | -570.3 | -408.2 | -625.7 | -604.1 | -527.8 |
| Net margin | - | - | - | -6,251.83% | -4,199.09% | -436.92% |
| EPS 2 | -6.940 | -12.75 | -5.730 | -7.215 | -6.216 | -4.988 |
| Free Cash Flow 1 | - | -303.8 | -334.8 | -333 | -625.6 | -259.3 |
| FCF margin | - | - | - | -3,327.54% | -4,348.44% | -214.63% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 8/10/22 | 3/23/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | 0.00167 | 11.12 | 3.162 | 3.191 |
| EBITDA 1 | - | - | - | - | - | -151.8 | -181.8 | -110.7 | -111.9 | -117 | -128.1 | -131.2 |
| EBIT 1 | -67.64 | -213.4 | -77.78 | -94.01 | -110.5 | -153.7 | -183.2 | -167.8 | -161.5 | -155.1 | -148.8 | -150.2 |
| Operating Margin | - | - | - | - | - | - | - | - | -9,673,524.55% | -1,395.17% | -4,707.48% | -4,706.92% |
| Earnings before Tax (EBT) 1 | -67.64 | -215.2 | -69.55 | -88.17 | -105.9 | -146 | -178.9 | -158 | -152.4 | -147.7 | -151.2 | -152.6 |
| Net income 1 | -67.64 | -201.1 | -70.49 | -90.35 | -102.6 | -144.8 | -179.5 | -150.8 | -146.6 | -143.5 | -146.7 | -148.5 |
| Net margin | - | - | - | - | - | - | - | - | -8,779,643.71% | -1,290.4% | -4,640.12% | -4,653.04% |
| EPS 2 | -1.750 | -3.320 | -1.030 | -1.320 | -1.500 | -1.810 | -2.200 | -1.772 | -1.658 | -1.578 | -1.670 | -1.772 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/22 | 3/23/23 | 5/12/23 | 7/31/23 | 11/14/23 | 2/29/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 465 | 382 | 500 | 393 | 435 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -304 | -335 | -333 | -626 | -259 |
| ROE (net income / shareholders' equity) | - | -199% | -78.5% | -102% | -150% | -116% |
| ROA (Net income/ Total Assets) | - | -142% | -64.6% | -83.6% | -80.3% | -85.2% |
| Assets 1 | - | 401.9 | 632.1 | 748.8 | 752.8 | 619.4 |
| Book Value Per Share 2 | - | 12.00 | 5.280 | 6.330 | 3.630 | 3.740 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 6.07 | 3.05 | 3.5 | 6.84 | 6.06 |
| Capex / Sales | - | - | - | 34.97% | 47.56% | 5.01% |
| Announcement Date | 8/10/22 | 3/23/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
37.99
USD
Average target price
57.44
USD
Spread / Average Target
+51.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.13% | 3.42B | |
| +64.23% | 55.07B | |
| -2.31% | 41.79B | |
| +44.36% | 40.22B | |
| -8.29% | 28.17B | |
| +11.97% | 26.28B | |
| -21.16% | 18.93B | |
| +7.54% | 13.03B | |
| +27.17% | 12.26B | |
| +25.72% | 12.21B |
- Stock Market
- Equities
- BHVN Stock
- Financials Biohaven Ltd.
